JP Morgan Conference Panelists Say Cost of Capital is a Critical Issue
By Murray W. Wolf
Not-for-profit health system executives might seem to be unlikely candidates for a panel discussion at a conference where fledgling biotech firms and other publicly traded companies vie for equity investors.
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
